Q2 Results

Mphasis eyes double-digit FY27 growth on strong deal pipeline, AI demand

Mphasis expects low double-digit growth in FY27, supported by a strong deal pipeline and AI-led opportunities, even as macroeconomic uncertainty weighs on traditional IT spending

Pharmacy retail stock Entero Healthcare zooms 33% in 1 week; hits new high

Entero Healthcare Solutions' share price moved higher by 4% to ₹2,095.30, also its new high, bouncing back 7% from its intraday low of ₹1,967 on Monday.

Data Patterns shares zoom 9% post Q2 show, nearly double from Jan lows

Data Patterns posted a profit after tax (PAT) of 21.97 crore in Q2 FY27 as against 49.19 crore in Q2 FY26, a reduction of 55.3 per cent year-on-year (YoY).

IRB Infra share price climbs 7% as toll collections boost Q2 earnings

IRB Infra share price target: MOFSL has retained its earnings estimates and reiterated a 'Buy' rating on IRB Infra stock, with a target price of ₹22.

Uno Minda zooms 26% in November, stock nears record high; here's why

Uno Minda's share price hit a 52-week high of ₹1,367.50, gaining 4% on the NSE in Monday's intraday deals.

ZEEL extends gains, rises 11% in 2 days as board to mull buyback, dividend

ZEEL settled with a bullish reversal candlestick pattern on its weekly charts, signalling a potential relief rally toward the 80 mark in the near term, show tech charts.

Pharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%

Divi's Labs, Laurus Labs, Sai Life Sciences and Glenmark Pharma quoted at their respective record highs in Monday's trade.

Multibagger stock: Sai Life Sciences surges 9% to record high after Q2 nos

Sai Life Sciences' consolidated net profit increased by 17 per cent Y-o-Y to ₹98 crore in the September quarter of FY27. Its revenue grew by 23 per cent Y-o-Y to ₹659 crore.

Jubilant FoodWorks dips 5% post Q2, but brokerages remain firm; here's why

MOFSL said it remains positive on Jubilant Food's medium-term outlook, supported by 5-7 per cent LFL growth potential, strong Popeyes momentum, and healthy international performance.

Voltas dips 8% in two sessions post Q2 earnings; Emkay retains 'Buy' rating

Analysts at Emkay retained 'Buy' rating on Voltas with a target price of ₹1,500 as valuations remain attractive and the stock trades near the lower end of the historical range.

Divis joins ₹3 trn market cap club; rallies 15% in 2 days post Q2 results

The stock price of Divi's Labs quoted higher for the 12th straight trading day, surging 32 per cent during the period.

Honasa Consumer gains 5% as brokerages raise target, earnings post Q2

In 2026 so far, Honasa shares have climbed 70 per cent and are up 76 per cent on a one-year basis, according to NSE data.

Tata Steel spurts 3% in Muhurat trading session post steady Q2 earnings

Tata Steel share price hit a high of ₹192.19, gaining over 3 per cent on the NSE in Sunday's Muhurat trading session.

Kirloskar Industries Q2 profit rises 5% to ₹105 crore, income up 17%

Kirloskar Industries Ltd (KIL) has reported a 5 per cent rise in consolidated profit after tax to Rs 105 crore in the quarter ended September 2026. The company had posted a consolidated PAT (profit after tax) of Rs 100.1 crore in the year-ago period. Consolidated income of the company during the second quarter rose to Rs 2,097.7 crore from Rs 1,790.1 crore in the year-ago period, KIL said in a statement. "Our material subsidiary, Kirloskar Ferrous Industries Limited, continued to deliver a resilient performance during the year, supported by operational stability, capacity optimisation and strong demand for its products across the sectors. On the real estate front, our wholly-owned subsidiary, Avante Spaces Limited (ASL), is progressing well. Our landmark Kothrud project is going well and moving forward on track, reinforcing our vision of creating premium, future-ready spaces that maximise value for our stakeholders," George Verghese, Managing Director, KIL, said. Kirloskar Industr

Tata Steel Q2 net profit up 18.2 per cent Y-o-Y, led by India operations

Consolidated revenue increased 11.5 per cent to Rs 65,436 crore, while EBITDA rose 14 per cent sequentially to Rs 10,665 crore, led by stronger India operations

Divi's Labs Q2 result: Net profit rises 64% to ₹1,127 cr on higher revenue

Divi's Laboratories Ltd on Saturday posted a sharp 63.57 per cent rise in net profit to Rs 1,127 crore in the September quarter due to higher revenues. The company posted a net profit of Rs 689 crore in the corresponding period of the previous fiscal year, a regulatory filing said. Revenue from operations rose 35.39 per cent to Rs 3,676 crore during the second quarter of FY27 from Rs 2,715 crore a year earlier, it said. Its total expenses rose to Rs 2,265 crore in the period under review from Rs 1,948 crore a year ago, it added. The company's net profit for the first half of the current fiscal year, however, declined 35.39 per cent to Rs 2,029 crore from Rs 2,568 crore in the year-ago period, the filing added.

Kwality Wall's Q2FY27 result: Revenue rises 44%, net loss at ₹17 crore

Kwality Wall's reported a net loss of ₹17.2 crore in Q2 FY27, compared with ₹100.2 crore a year ago; revenue rose 44% year-on-year but fell 47.2% sequentially

Street remains bullish on Titan Company post Q2, stronger Q3 prospects

Analysts remain positive on Titan after its Q2 earnings, citing resilient jewellery demand, improving watch and eyewear performance, and stronger festive prospects in Q3

Gland Pharma Q2FY27 results: Net profit rises 58% to ₹290.75 crore

Gland Pharma on Friday posted a 58.29 per cent rise in consolidated net profit to Rs 290.75 crore in the September quarter, driven by strong execution across businesses. The company had reported a net profit of Rs 183.68 crore in the year-ago period. The pharmaceutical company's revenue from operations rose to Rs 1,833.58 crore in the quarter under review from Rs 1,486.87 crore a year ago, the company said in a regulatory filing. Total expenses also rose to Rs 1,471.69 crore in the July-September period from Rs 1,287.12 crore a year earlier, it said. The company launched four molecules -- Sugammadex, Erythromycin, Fluorouracil and Atropine sulfate -- in the US this quarter, it said in a release. Gland Pharma Executive Chairman Srinivas Sadu said, "We delivered another quarter of strong growth...driven by strong execution across our businesses. Our CDMO business grew 31 per cent year-on-year, supported by expanding customer engagements, strategic partnerships and a robust opportuni

Aster DM Quality Care Q2 net profit more than doubles to ₹262 crore

The hospital chain reported revenue of ₹2,829 crore in Q2FY27, driven by higher patient volumes, improved occupancy, complex procedures and growth in medical value travel